Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | KMO | O15229 | 4/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | POLA1 | P09884 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10982509 | 0.81 | NPC1 (0.51) | NPC1RAB9ABRAFPDE4APDE4B | |
| SCHEMBL7777633 | 0.80 | ADORA2A (0.56) | ADORA1ADORA2ADHFR | |
| SCHEMBL10988115 | 0.77 | HTR2B (0.53) | NPC1RAB9APDE4DKDM4EALDH1A1 | |
| SCHEMBL7769989 | 0.75 | ADORA2A (0.50) | ADORA1ADORA2ADHFR | |
| SCHEMBL7776145 | 0.74 | HRH2 (0.45) | NPC1RAB9ABRAFADORA1ADORA2A | |
| SCHEMBL7774460 | 0.74 | ADORA2A (0.55) | BRAFADORA1ADORA2AKDM4EESR2 | |
| SCHEMBL9134038 | 0.73 | ADORA2A (0.49) | ADORA1ADORA2ADHFR | |
| SCHEMBL7777554 | 0.71 | ADORA2A (0.58) | NPC1RAB9AADORA1ADORA2AKDM4E | |
| SCHEMBL7774730 | 0.71 | ADORA2A (0.56) | ADORA1ADORA2ACYP3A4MAPT | |
| SCHEMBL7777511 | 0.69 | MAPT (0.50) | NPC1RAB9APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2001505911-A | — | — | 2001-05-08 | — | — | JP | claimed |
| EP-0948331-A2 | METHOD FOR TREATING MULTIPLE SCLEROSIS | PHARMACIA & UPJOHN COMPANY (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1998025596-A2 | USE OF A 6-ARYL PYRIMIDINE COMPOUND FOR TREATING MULTIPLE SCLEROSIS | PHARMACIA & UPJOHN COMPANY (US) | 1998-06-18 | — | — | WO | claimed |
| US-5434157-A | Active against herpes, hepatitis, papovavirus | THE UPJOHN COMPANY (US) | 1995-07-18 | — | — | US | claimed |
| EP-0948331-A2 | METHOD FOR TREATING MULTIPLE SCLEROSIS | PHARMACIA & UPJOHN COMPANY (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998025596-A2 | USE OF A 6-ARYL PYRIMIDINE COMPOUND FOR TREATING MULTIPLE SCLEROSIS | PHARMACIA & UPJOHN COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5554617-A | Method for treating cancer with 6-aryl pyrimidine compounds | THE UPJOHN COMPANY (US) | 1996-09-10 | — | — | US | disclosed |
| US-5434157-A | Active against herpes, hepatitis, papovavirus | THE UPJOHN COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| US-5002951-A | 2-amino-5-halo-4-pyrimidinol for bactericides and antiprotozoa agent | THE UPJOHN COMPANY (US) | 1991-03-26 | — | — | US | disclosed |
| US-4665077-A | IMMUNOREGULATORY AGENTS | THE UPJOHN COMPANY (US) | 1987-05-12 | — | — | US | disclosed |
| US-4619933-A | 6-aryl pyrimidines for treating aplastic anemia | THE UPJOHN COMPANY (US) | 1986-10-28 | — | — | US | disclosed |
| US-4543248-A | Method for immunoregulation with 6-aryl pyrimidine compounds | THE UPJOHN COMPANY (US) | 1985-09-24 | — | — | US | disclosed |
| US-4507302-A | Method for treating arthritis with 6-aryl pyrimidine compounds | THE UPJOHN COMPANY (US) | 1985-03-26 | — | — | US | disclosed |